RxDoctor Payments Data

Wallace Curry, MD

Urology · Rock Springs, WYNPI 1407892482

Payments from drug & device makers

What this record shows

Cook Incorporated accounts for 60.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $848 and has fallen 80.2% since, to $168 in 2023.

$1,390in general payments, 2019–2025

Across 31 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$835
  • Cook Medical LLC$146
  • Medtronic$78
  • Astellas Pharma US Inc$53
  • Procept Biorobotics Corporation$47
  • Johnson & Johnson$36
  • plus $194 from 10 others

What the payments were for

  • Travel & lodging$77456%
  • Food & beverage$61644%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$40,510
Medicare patients
164
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron31$17,407
Tamsulosin Hcl266$3,201
Finasteride157$2,318
Methenamine Hippurate35$1,921
Silodosin29$1,706
Estradiol21$1,554
Testosterone17$1,406
Alfuzosin Hcl ErAlfuzosin Hcl57$1,114
Solifenacin Succinate45$1,079
Potassium Citrate ErPotassium Citrate12$979
Sodium Chloride0.9 % Sodium Chloride18$598
Tolterodine Tartrate15$422
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$382
Gentamicin Sulfate14$269
Cephalexin38$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$53$17,40731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other urology in Rock Springs

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →